Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference74 articles.
1. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer;Sandler;N Engl J Med,2006
2. Modes of resistance to antiangiogenic therapy;Bergers;Nat Rev Cancer,2008
3. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV nonsmall-cell lung cancer after disease progression on platinum-based therapy (revel): a multicentre, double-blind, randomised phase 3 trial;Garon;Lancet,2014
4. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated nonsmall-cell lung cancer (lume-lung 1): A phase 3, double-blind, randomised controlled trial;Reck;Lancet Oncol,2014
5. Metastatic nonsmall cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer;Chinese Medical Journal;2024-01-22
2. Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma;Translational Oncology;2023-12
3. Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer;Journal of Environmental Pathology, Toxicology and Oncology;2023
4. The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study;Scientific Reports;2022-08-26
5. Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions;Cells;2022-05-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3